Breast Cancer

Patient-reported satisfaction was higher in patients with breast cancer treated with olanzapine vs those who underwent treatment with placebo.

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Breast oncologist Jade E. Jones, MD, says she tries to send patients with HR-positive BRCA-mutant TNBC to clinical trials that use PARP inhibitors.

Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.

T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive breast cancer/triple-negative breast cancer in DESTINY-Breast04.